IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine

Campos, Ivana Barros de; Herd, Muriel; Moffitt, Kristin; Lu, Ying‐Jie; Darrieux, Michelle; Malley, Richard; Leite, Luciana C. C.; Gonçalves, Viviane Maimoni

doi:10.1016/j.vaccine.2017.01.030

Cited by 22 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Campos and coworkers showed that PWCV from RM200 cells was capable of inducing non-capsular antibodies to protect mice against invasive pneumococcal disease and reduce nasopharyngeal (NP) carriage via IL-17A production. The authors demonstrated that PWCV antibodies were able to bind to different encapsulated strains, activate the complement, and induce phagocytosis of pneumococcus in vitro [56].…”

Section: Preclinical Assaysmentioning

confidence: 99%

Next-Generation Whole-Cell Pneumococcal Vaccine

2019

View full text Add to dashboard Cite

Streptococcus pneumoniae remains a major public health hazard. Although Pneumococcal Conjugate Vaccines (PCVs) are available and have significantly reduced the rate of invasive pneumococcal diseases, there is still a need for new vaccines with unlimited serotype coverage, long-lasting protection, and lower cost to be developed. One of the most promising candidates is the Whole-Cell Pneumococcal Vaccine (WCV). The new generation of whole-cell vaccines is based on an unencapsulated serotype that allows the expression of many bacterial antigens at a lower cost than a recombinant vaccine. These vaccines have been extensively studied, are currently in human trial phase 1/2, and seem to be the best treatment choice for pneumococcal diseases, especially for developing countries.

show abstract

Section: Preclinical Assaysmentioning

confidence: 99%

Next-Generation Whole-Cell Pneumococcal Vaccine

2019

View full text Add to dashboard Cite

show abstract

“…We have studied a killed pneumococcal whole-cell preparation that elicits protection against subsequent pneumococcal nasopharyngeal challenge. [16][17][18][19][20][21][22][23][24] When delivered either intranasally (I.N.) with cholera toxin (CT) as an adjuvant, or subcutaneously (S.C.) with alum, killed pneumococci can elicit a multipronged immune response.…”

Section: Introductionmentioning

confidence: 99%

Generation of protective pneumococcal-specific nasal resident memory CD4+ T cells via parenteral immunization

et al. 2020

Self Cite

View full text Add to dashboard Cite

The generation of tissue-resident memory T cells (T RM ) is an essential aspect of immunity at mucosal surfaces, and it has been suggested that preferential generation of T RM is one of the principal advantages of mucosally administered vaccines. We have previously shown that antigen-specific, IL-17-producing CD4 + T cells can provide capsular antibody-independent protection against nasal carriage of Streptococcus pneumoniae; but whether pneumococcus-responsive T RM are localized within the nasal mucosa and are sufficient for protection from carriage has not been determined. Here, we show that intranasal administration of live or killed pneumococci to mice generates pneumococcus-responsive IL-17A-producing CD4 + mucosal T RM. Furthermore, we show that these cells are sufficient to mediate long-lived, neutrophil-dependent protection against subsequent pneumococcal nasal challenge. Unexpectedly, and in contrast with the prevailing paradigm, we found that parenteral administration of killed pneumococci also generates protective IL-17A + CD4 + T RM in the nasal mucosa. These results demonstrate a critical and sufficient role of T RM in prevention of pneumococcal colonization, and further that these cells can be generated by parenteral immunization. Our findings therefore have important implications regarding the generation of immune protection at mucosal surfaces by vaccination.Mucosal Immunology (2020) 13:172-182; https://doi.

show abstract

“…An engineered pneumococcal strain, which lacks a polysaccharide capsule and toxins has been tested as an inactivated whole cell vaccine in mice (169,170). In combination with alum and administered subcutaneously to mice this whole cell pneumococcal vaccine induces antibodies binding to different encapsulated strains, activating the complement system and inducing phagocytosis of the bacteria in vitro (171). In a Phase I clinical trial in healthy adults this vaccine elicited antibodies to a range of pneumococcal proteins including multiple conserved antigens, as well as T cell responses (172,173).…”

Section: Future Perspectives To Improve Vaccination Of the Older Popumentioning

confidence: 99%

Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Wagner

Weinberger

2020

Front. Immunol.

View full text Add to dashboard Cite

Infectious diseases are a major cause for morbidity and mortality in the older population. Demographic changes will lead to increasing numbers of older persons over the next decades. Prevention of infections becomes increasingly important to ensure healthy aging for the individual, and to alleviate the socioeconomic burden for societies. Undoubtedly, vaccines are the most efficient health care measure to prevent infections. Age-associated changes of the immune system are responsible for decreased immunogenicity and clinical efficacy of most currently used vaccines in older age. Efficacy of standard influenza vaccines is only 30-50% in the older population. Several approaches, such as higher antigen dose, use of MF59 as adjuvant and intradermal administration have been implemented in order to specifically target the aged immune system. The use of a 23-valent polysaccharide vaccine against Streptococcus pneumoniae has been amended by a 13-valent conjugated pneumococcal vaccine originally developed for young children several years ago to overcome at least some of the limitations of the T cell-independent polysaccharide antigens, but still is only approximately 50% protective against pneumonia. A liveattenuated vaccine against herpes zoster, which has been available for several years, demonstrated efficacy of 51% against herpes zoster and 67% against post-herpetic neuralgia. Protection was lower in the very old and decreased several years after vaccination. Recently, a recombinant vaccine containing the viral glycoprotein gE and the novel adjuvant AS01B has been licensed. Phase III studies demonstrated efficacy against herpes zoster of approx. 90% even in the oldest age groups after administration of two doses and many countries now recommend the preferential use of this vaccine. There are still many infectious diseases causing substantial morbidity in the older population, for which no vaccines are available so far. Extensive research is ongoing to develop vaccines against novel targets with several vaccine candidates already being clinically tested, which have the potential to substantially reduce health care costs and to save many lives. In addition to the development of novel and improved vaccines, which specifically target the aged immune system, it is also important to improve uptake of the existing vaccines in order to protect the vulnerable, older population.

show abstract

IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine

Cited by 22 publications

References 45 publications

Next-Generation Whole-Cell Pneumococcal Vaccine

Next-Generation Whole-Cell Pneumococcal Vaccine

Generation of protective pneumococcal-specific nasal resident memory CD4+ T cells via parenteral immunization

Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Contact Info

Product

Resources

About